NCT06216132View on ClinicalTrials.gov

Study of the BIOPIN 6 Naltrexone Implant in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

April 18, 2025

Study Completion Date

April 25, 2025

Conditions
Opioid Use Disorder
Interventions
COMBINATION_PRODUCT

BIOPIN-6 Active Implant with Naltrexone

An extended release formulation of naltrexone implanted in the subcutaneous space.

DEVICE

BIOPIN-6 Placebo Implant

The placebo will be an implant consisting of the poly-d-l Lactic Acid and polycaprolactone contained in BIOPIN 6 without naltrexone.

Trial Locations (1)

84107

JBR Clinical Research, Salt Lake City

Sponsors
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Laboratory Corporation of America

INDUSTRY

collaborator

Cognitive Research Corporation

INDUSTRY

lead

Drug Delivery Company, LLC DBA Akyso Pharmaceuticals

INDUSTRY